Prolactin and the Hair Follicle

ABS-201 for Hair Loss: What the Data on Absci's "AI-Designed" Antibody Actually Shows

ABS-201 is the prolactin receptor antibody Absci describes as AI-designed, funded by a $100 million share sale that included $40 million from Eli Lilly. Absci has released Phase 1 safety data and no hair data yet.

$40M
Lilly's share of the $100M offering
5,398,111 shares at $7.41. Absci says it buys no rights to ABS-201
65+ days
estimated half-life
interim and blinded. 24 of 32 volunteers got one IV dose, 8 placebo
0
human hair results released
Absci anticipates 13-week interim data in December 2026

Key takeaways

  • ABS-201 is an investigational IgG1 antibody designed to block the prolactin receptor, given intravenously in the single-dose part of its trial and by subcutaneous injection in the part that measures hair.
  • Eli Lilly bought $40 million of a $100 million share offering in June 2026, and Absci says that buys Lilly no rights to ABS-201.
  • The only human data released are blinded safety and blood-level results from 32 healthy adults, 24 on one intravenous dose and 8 on placebo: no serious adverse events, and an estimated half-life of at least 65 days, as reported by Absci.
  • The hair case rests on cultured human scalp follicles, mouse studies, an uncontrolled patent study in 11 macaques and an open-label result for a different PRLR antibody. We found no placebo-controlled human hair counts for any prolactin receptor antibody as of November 2026.
Contents9 sections

ABS-201 is an injectable antibody that Absci says blocks the prolactin receptor (PRLR). Absci raised $100 million in June 2026 to take it through trials in pattern hair loss and endometriosis, with Eli Lilly buying $40 million of the shares.

The short answer: ABS-201 has not been shown to grow hair in people. Absci's first-in-human trial (NCT07317544) has released only blinded safety and blood-level data: 32 healthy adults, 24 on a single intravenous dose and 8 on placebo. Absci reports no serious adverse events and an estimated half-life of at least 65 days. The hair case rests on cultured human scalp follicles, mouse studies, an uncontrolled study in 11 balding macaques and a company-reported open-label result for a different PRLR antibody, HMI-115.

What is ABS-201?

ABS-201 is an investigational IgG1 monoclonal antibody, and Absci Corporation is developing it for androgenetic alopecia and endometriosis. It is not approved anywhere.

As of 15 November 2026 its only registered trial is HEADLINE, at five sites in Australia. The single-dose part gives ABS-201 by intravenous infusion, and the multiple-dose part that measures hair gives it by subcutaneous injection. Absci's annual report for 2025 calls it "engineered with an extended half-life to support a patient-friendly dosing interval."

Did Eli Lilly invest $100 million in ABS-201?

No. Lilly bought $40 million of a $100 million offering.

Absci's pricing release of 24 June 2026 describes 13,495,277 shares sold at $7.41, to Lilly alongside five named investment firms and an unnamed large investment management firm. The prospectus supplement says 5,398,111 of those shares were "allocated for purchase by Eli Lilly and Company," and it itemizes only Lilly's allocation.

Absci's second-quarter release says the partnership "does not confer any program rights to Eli Lilly," and that a Lilly representative has joined its Endometriosis Advisory Board.

What does "AI-designed" mean for ABS-201?

For Absci it means ABS-201 came out of its drug creation platform. Generative AI models propose antibody sequences, and an automated wet lab tests them in cycles the company says take about six weeks. The platform has two modes: de novo design against "epitopes with no known protein binders," and AI optimization of leads for affinity, developability and other properties.

We found no public statement of which mode produced ABS-201. The annual report for 2025 says only that Absci's internal programs were generated using "de novo antibody design, multi-parameter candidate optimization and reverse immunology approaches." We found no disclosure of ABS-201's design route or sequence.

A May 2025 investor presentation calls its leads "AI-optimized high affinity leads," with nanomolar to sub-nanomolar affinity for human PRLR and cross-reactivity with the monkey receptor. It reports a more than threefold longer half-life in monkeys than HMI-115, an earlier anti-PRLR antibody. Absci says its first two programs reached the clinic about two years after initial AI-driven design, at about $15 million each.

How does prolactin affect hair growth?

Prolactin pushes follicles into catagen, the regression phase, in cultured human scalp follicles and in mice. In mice, removing prolactin signaling brings the next growth phase forward.

The main organ-culture study found both prolactin and its receptor in the epithelium of human scalp follicles. Adding 400 ng/ml of prolactin for eight days slowed hair shaft growth, about 1.3 mm against 1.6 mm in controls, with 63 follicles per group. It also left 45% of follicles in full anagen against more than 70% of controls (Foitzik et al. 2006).

The 400 ng/ml dose is far above the 5 to 20 ng/ml the authors give as normal for men, and most of the follicles came from the occipital scalp, which balding spares. Anagen's treatment science page on prolactin and the hair follicle sets out this biology alongside the HMI-115 record.

The mouse evidence lines up. Prolactin induced premature catagen in cultured mouse skin (Foitzik et al. 2003). Mice lacking the receptor molted earlier, by 29 days in females and 4 days in males, and grew slightly longer, coarser hair (Craven et al. 2001). Suppressing pituitary prolactin advanced regrowth in young female mice by 3.5 days (Craven et al. 2006). Bayer's research antibody against PRLR, 005-C04, stimulated hair regrowth in female mice, and also made them reversibly infertile and impaired lactation (Otto et al. 2015).

The monkey evidence is a Bayer patent application rather than a paper. Eleven stump-tailed macaques aged 12 to 27 got 40 mg/kg of an anti-PRLR antibody called mat3, injected subcutaneously twice a month for about six months. The species balds in a human-like pattern.

Terminal hair count rose in previously bald scalp in 9 of 11, by 50 to 220 hairs/cm² in responders. One elderly female died under anesthesia in week 16 (May et al. 2019). There was no placebo group.

Six months after dosing stopped, the patent reports no further gain and only a marginal drop. Absci's November 2026 slides say the growth "remains and improves several years post cessation," and that the study was commissioned by Andreas Busch while he was at Bayer. As of 15 November 2026 we found no peer-reviewed publication of the macaque study in PubMed.

Human data on prolactin and hair loss conflict. High prolactin has been described alongside an androgenetic alopecia-like pattern of hair loss, which the organ-culture authors offered their findings to explain (Foitzik et al. 2006). But a 1980 letter titled "Increased hair loss as a side effect of bromocriptine treatment" reported hair loss on bromocriptine, which lowers prolactin (Blum and Leiba 1980). We read only the letter's title. And 37 men balding before age 30 showed only a borderline trend toward higher prolactin (Stárka et al. 2004).

Absci also cites its own unpublished analysis of 165,649 men in UK Biobank, linking genetically higher PRLR levels, estimated from the variant rs6451196, to more severe balding. We found no peer-reviewed publication of that analysis.

Has ABS-201 been tested in people?

Yes, in one trial, which has reported only safety and blood-level results.

HEADLINE (NCT07317544) is a Phase 1/2a, randomized, quadruple-masked, placebo-controlled trial that began on 3 December 2025 and plans to enroll up to 227 adults aged 18 to 65. The primary endpoint is safety, including the PHQ-9 and GAD-7 depression and anxiety questionnaires. Secondary endpoints include blood prolactin, anti-drug antibodies and, in the multiple-dose cohorts, change in target area hair count and hair width at week 26.

Absci reported interim, blinded data from the single-dose part on 24 June 2026. Four cohorts of eight got 150, 450, 900 or 1,800 mg intravenously or placebo, at a 3:1 ratio. As of an 8 June 2026 cutoff Absci reported no serious adverse events and one moderate headache judged unlikely to be related. Five participants had mild treatment-related events, headache the most common, in four participants.

The data are blinded and pooled, so those counts include placebo recipients. With 24 people on drug, zero serious events cannot rule out a rate of up to about 1 in 8, by the rule of three (our arithmetic). And the half-life estimate of "at least 65 days" rests on follow-up that reached day 56 in the lower-dose cohorts, which is shorter than the estimate itself.

The multiple-dose part is the one that measures hair. It enrolls people rated Norwood-Hamilton III vertex to V in three cohorts of about 49, on 300, 600 or 1,200 mg subcutaneously or placebo over 26 weeks. At 3:1 that is roughly 37 on drug and 12 on placebo per dose, by our arithmetic. Absci's 12 November 2026 release says dosing is continuing and that the company "anticipates reporting 13-week interim proof-of-concept data from this study in December 2026 and full 26-week proof-of-concept data in early 2027." The registry estimates primary completion in July 2028.

The annual report says the cohort size can detect "a nominally significant difference in target area hair count." But the analysis "would not be multiplicity-adjusted and report only nominal p-values, consistent with its exploratory nature."

The preclinical package also comes from Absci. In six-day organ cultures of frontotemporal male scalp skin, the company reports that ABS-201 prolonged anagen, raised IGF-1 and FGF7 and protected K15-positive stem cells, even without added prolactin. In shaved female mice, up to 11 per group, Absci reports full coat regrowth by day 22 with injected ABS-201, against about one third with daily 5% topical minoxidil (p<0.0001).

As of 15 November 2026 we found no peer-reviewed primary research on ABS-201 in PubMed, only a mention in a review article. And a shaved-mouse test measures how quickly resting follicles re-enter growth, the part of the cycle prolactin controls in mice (Craven et al. 2006). It measures that in skin that does not develop pattern hair loss.

Has a prolactin receptor antibody grown hair in people?

As of 15 November 2026 we found no placebo-controlled human hair results for any prolactin receptor antibody.

The closest test is HMI-115, which Hope Medicine licensed from Bayer in April 2019, according to the company's 2022 release. Its randomized, placebo-controlled Phase 2 in 192 men with androgenetic alopecia (NCT06118866) ran subcutaneous dosing for 24 weeks, with non-vellus target area hair count as the primary endpoint. ClinicalTrials.gov lists it as completed on 28 November 2024 with no results posted, and we found no company release of the outcome.

An open-label study in 16 men and women (NCT05324293) completed in September 2023, also without posted results. Hope Medicine's January 2024 release reported a mean gain of 14 non-vellus hairs per cm² from baseline in the 12 men of that study, with no placebo group (Hope Medicine 2024).

Our treatment science page on prolactin and the hair follicle goes through the HMI-115 record in more detail. Anagen's November 2026 tier list of hair loss treatments places ABS-201 in C tier pending human efficacy data.

What is still unknown about ABS-201?

Whether ABS-201 grows hair on a human scalp is unknown. So are the size of any effect against placebo, the durability after dosing stops, and whether it helps women, since the hair cohorts are defined by the Norwood-Hamilton scale.

The first planned readout is 13-week interim data from a trial whose own hair endpoint is at week 26. The durability claim rests on the macaque study, where Absci's later materials add unpublished observations out to four years.

The dosing schedule is a model too. Absci's November 2026 presentation projects two to three injections over six months from popPK modeling of interim data, and labels its 400 mg example "illustrative for modeling purposes."

Reproductive effects need study, because prolactin receptor signaling is required for lactation. A woman with two loss-of-function PRLR variants did not lactate after either delivery (Kobayashi et al. 2018). Three sisters with one such variant had high prolactin, two with infrequent periods and one with infertility (Newey et al. 2013). Bayer's research antibody made female mice reversibly infertile (Otto et al. 2015).

Absci's slides describe people with reduced PRLR signaling as "otherwise in good health," with "no apparent impact on fertility." The HEADLINE protocol requires participants to avoid pregnancy, excludes anyone with a history of postpartum depression or perimenopausal mood instability, and tracks blood prolactin and mood.

Frequently asked questions

What is ABS-201?

An investigational antibody that Absci describes as blocking the prolactin receptor, in development for androgenetic alopecia and endometriosis. Its current trial gives it by infusion or subcutaneous injection, and it is not approved anywhere. The only human data released are safety and blood-level results from 32 healthy volunteers, 24 of whom received ABS-201.

Does ABS-201 work for hair loss?

Nobody knows yet. Absci had released no human hair data as of 15 November 2026, so the case rests on cultured human scalp follicles, mouse studies and an uncontrolled patent study in 11 macaques. Absci says it anticipates reporting 13-week interim proof-of-concept data in December 2026 and full 26-week data in early 2027.

How much did Eli Lilly invest in Absci?

$40 million, for 5,398,111 shares in Absci's $100 million underwritten offering, priced on 24 June 2026. Absci's release names five other investors and an unnamed firm among the participants. Absci says the deal gives Lilly no rights to ABS-201, and that a Lilly representative joined its Endometriosis Advisory Board.

How is ABS-201 given, and how often?

In the HEADLINE trial, single doses went in intravenously and repeat doses are given by subcutaneous injection at 300, 600 or 1,200 mg. Absci estimates a half-life of at least 65 days from interim data and models two to three injections over six months. That schedule is a projection, and it has not been tested for hair outcomes.

Is ABS-201 the same as HMI-115?

No. Both block the prolactin receptor, but HMI-115 is a separate antibody that Hope Medicine licensed from Bayer. HMI-115 completed a placebo-controlled Phase 2 in 192 men with androgenetic alopecia in November 2024, and as of November 2026 its results had not been posted on ClinicalTrials.gov.

Can I get ABS-201 now?

No. As of 15 November 2026 its only registered trial is HEADLINE, which enrolls participants at sites in Australia, and ABS-201 is not approved anywhere. Two treatments are FDA approved for pattern hair loss, topical minoxidil and oral finasteride 1 mg, and a clinician can advise on what fits your history.

References

  1. Foitzik K, Krause K, Conrad F, Nakamura M, Funk W, Paus R. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol. 2006;168(3):748-756. PMID: 16507890. DOI: 10.2353/ajpath.2006.050468Cited in How does prolactin affect hair growth? (2)
  2. Foitzik K, Krause K, Nixon AJ, Ford CA, Ohnemus U, Pearson AJ, Paus R. Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen. Am J Pathol. 2003;162(5):1611-1621. PMID: 12707045. DOI: 10.1016/S0002-9440(10)64295-2Cited in How does prolactin affect hair growth?
  3. Craven AJ, Ormandy CJ, Robertson FG, et al. Prolactin signaling influences the timing mechanism of the hair follicle: analysis of hair growth cycles in prolactin receptor knockout mice. Endocrinology. 2001;142(6):2533-2539. PMID: 11356702. DOI: 10.1210/endo.142.6.8179Cited in How does prolactin affect hair growth?
  4. Craven AJ, Nixon AJ, Ashby MG, et al. Prolactin delays hair regrowth in mice. J Endocrinol. 2006;191(2):415-425. PMID: 17088411. DOI: 10.1677/joe.1.06685Cited in How does prolactin affect hair growth? · Has ABS-201 been tested in people?
  5. Otto C, Särnefält A, Ljungars A, et al. A neutralizing prolactin receptor antibody whose in vivo application mimics the phenotype of female prolactin receptor-deficient mice. Endocrinology. 2015;156(11):4365-4373. PMID: 26284426. DOI: 10.1210/en.2015-1277Cited in How does prolactin affect hair growth? · What is still unknown about ABS-201?
  6. May E, Jodl SJ, Krätzschmar J, Otto C. Prolactin receptor antibody for male and female pattern hair loss. WO2019011719A1. Bayer Pharma AG. 2019. Published 17 January 2019. https://patents.google.com/patent/WO2019011719A1/enCited in How does prolactin affect hair growth?
  7. Blum I, Leiba S. Increased hair loss as a side effect of bromocriptine treatment. N Engl J Med. 1980;303(24):1418. PMID: 7437092. DOI: 10.1056/NEJM198012113032416Cited in How does prolactin affect hair growth?
  8. Stárka L, Cermáková I, Dusková M, et al. Hormonal profile of men with premature balding. Exp Clin Endocrinol Diabetes. 2004;112(1):24-28. PMID: 14758568. DOI: 10.1055/s-2004-815723Cited in How does prolactin affect hair growth?
  9. Newey PJ, Gorvin CM, Cleland SJ, et al. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013;369(21):2012-2020. PMID: 24195502. DOI: 10.1056/NEJMoa1307557Cited in What is still unknown about ABS-201?
  10. Kobayashi T, Usui H, Tanaka H, Shozu M. Variant prolactin receptor in agalactia and hyperprolactinemia. N Engl J Med. 2018;379(23):2230-2236. PMID: 30575453. DOI: 10.1056/NEJMoa1805171Cited in What is still unknown about ABS-201?
  11. ClinicalTrials.gov. NCT07317544: Study of ABS-201 evaluating single and multiple ascending doses in adults with and without androgenetic alopecia (HEADLINE). Sponsor Absci Pty Ltd. Record last updated 28 October 2026; accessed 15 November 2026. https://clinicaltrials.gov/study/NCT07317544
  12. Absci Corporation. Absci announces pricing of $100 million underwritten offering with leading strategic and financial investors. Press release (Form 8-K, Exhibit 99.1), 24 June 2026. https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233dex991.htm
  13. Absci Corporation. Prospectus supplement, 13,495,277 shares of common stock (Form 424B5), 24 June 2026. https://www.sec.gov/Archives/edgar/data/1672688/000119312526281131/d76291d424b5.htm
  14. Absci Corporation. Absci announces positive interim Phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the prolactin receptor (PRLR). Press release (Form 8-K, Exhibit 99.1), 24 June 2026. https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/exhibit991-26x06x23pr.htm
  15. Absci Corporation. Absci reports business updates and second quarter 2026 financial and operating results. Press release (Form 8-K, Exhibit 99.1), 11 August 2026. https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm
  16. Absci Corporation. Absci reports business updates and third quarter 2026 financial and operating results. Press release (Form 8-K, Exhibit 99.1), 12 November 2026. https://www.sec.gov/Archives/edgar/data/1672688/000167268826000150/exhibit991-2026q310xqpr.htm
  17. Absci Corporation. Annual report on Form 10-K for the year ended 31 December 2025. Filed 24 March 2026. https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htm
  18. Absci Corporation. Corporate presentation, November 2026 (Form 8-K, Exhibit 99.2), 12 November 2026. https://www.sec.gov/Archives/edgar/data/1672688/000167268826000150/corporatepresentationnov.htm
  19. Absci Corporation. Pipeline program updates presentation (Form 8-K, Exhibit 99.2), 13 May 2025. https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/pipelineprogramupdatesma.htm
  20. ClinicalTrials.gov. NCT06118866: A study to assess the efficacy and safety of HMI-115 in male subjects with androgenetic alopecia. Sponsor Hope Medicine (Nanjing) Co., Ltd. Accessed 15 November 2026. https://clinicaltrials.gov/study/NCT06118866
  21. ClinicalTrials.gov. NCT05324293: To evaluate the safety, tolerability and efficacy in male and female with AGA treated with HMI-115 over a 24-week treatment period. Sponsor Hope Medicine (Nanjing) Co., Ltd. Accessed 15 November 2026. https://clinicaltrials.gov/study/NCT05324293
  22. Hope Medicine, Hope Medicine announces US FDA clearance for Phase II clinical trial of a first-in-class monoclonal antibody HMI-115 in androgen alopecia. Press release, 25 January 2022. https://www.biospace.com/hope-medicine-announces-us-fda-clearance-for-phase-ii-clinical-trial-of-a-first-in-class-monoclonal-antibody-hmi-115-in-androgen-alopecia
  23. Hope Medicine, Positive outcome from a Phase Ib study in Australia treating patients with androgenic alopecia. Press release (PR Newswire), 14 January 2024. https://www.biospace.com/positive-outcome-from-a-phase-ib-study-in-australia-treating-patients-with-androgenic-alopeciaCited in Has a prolactin receptor antibody grown hair in people?

This article is for educational purposes only and is not medical or investment advice. ABS-201 and HMI-115 are investigational antibodies that are not approved by the FDA or any other regulator for any use, and statements about them are attributed to their developers and have not been independently verified. Topical minoxidil and oral finasteride 1 mg are FDA approved for pattern hair loss; oral minoxidil, dutasteride, topical finasteride and spironolactone are used off-label, and whether to use any prescription treatment is a decision for a licensed clinician who knows your history. Compounded products, including those Anagen offers, are not FDA approved.

Who wrote and reviewed this

Written by

Andrew Bakst

Co-founder, HairDAO

39 articles on the Anagen blog

First published
Last updated
References
23 sources

Start your personalised plan

Answer a few questions. We'll take it from there.

Take the hair assessment

Keep reading